Top Markets
#1 CyberDEX CyberDEX +372.54%
#2 OVERTAKE OVERTAKE +56.57%
#3 ALEO ALEO +43.43%
#4 Nillion Nillion +34.21%
#5 Clearpool Clearpool +27.85%
#6 Playnance Playnance +23.56%
#7 deBridge deBridge +23.20%
#8 龙虾 (Lobster) 龙虾 (Lobster) +19.17%
#9 AUKI AUKI +18.69%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.88%
Coin of the day
CyberDEX CyberDEX
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCI
Clasificación en acciones #37499
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998,... Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Precio por acción
$0.05897422
Última sincronización: 2024-04-02
Capitalización bursátil
$1.64M
Cambio (1 día)
0.07%
Cambio (1 año)
-60.68%
País
CA
Comercio Intellipharmaceutics International Inc. (IPCI)

Categoría

Healthcare
Ratio P/S de Intellipharmaceutics International Inc. (IPCI)
Ratio P/S al September 2026 TTM: 75.52
Según los informes financieros más recientes y el precio de las acciones de Intellipharmaceutics International Inc., el ratio P/S actual (TTM) es 75.52. Al final de 2021, el ratio P/S era 53.73.
Historial del ratio P/S de Intellipharmaceutics International Inc. desde 1999 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
2026 (TTM) 75.52 114.31%
2022 35.24 -34.41%
2021 53.73 2,358.50%
2020 2.19 -5.37%
2019 2.31 151.70%
2018 0.92 -80.84%
2017 4.79 -85.55%
2016 33.15 171.91%
2015 12.19 61.06%
2014 7.57 -85.08%
2013 50.74 -86.99%
2012 390.00 315.68%
2011 93.82 375.52%
2010 19.73 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 22.45K 2.75%
2000 21.84K 14,851.44%
1999 146.10 0.00%
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.44 -86.17%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
26.12 -65.41%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.76 -95.03%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
12.01 -84.10%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH